LOGIN  |  REGISTER
Amneal Pharmaceuticals
Astria Therapeutics

ProPhase Labs to Present at the 2025 ThinkEquity Conference

October 24, 2025 | Last Trade: US$0.37 0.0074 -1.96

UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.

Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 11AM ET on October 30th. One-on-one investor meetings will be held throughout the day. Interested investors can register to attend and schedule one-on-one meetings here: https://www.meetmax.com/sched/event_121867/conference_home.html

The presentation will also be live-streamed at the following link:
https://event.summitcast.com/view/NX3WagbdCmRzBGMxdc3ia6/guest_book?session_id=PDgxE2V2WRZcL6RynfToZv

About ProPhase Labs Inc.

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com

Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

Chimerix

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page